
Voyager Therapeutics, Inc. (NASDAQ:VYGR – Free Report) – Analysts at HC Wainwright dropped their FY2026 earnings per share estimates for Voyager Therapeutics in a report issued on Friday, November 13th. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings of ($1.41) per share for the year, down from their previous estimate of ($1.32). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Voyager Therapeutics’ current full-year earnings is ($1.62) per share. HC Wainwright also issued estimates for Voyager Therapeutics’ Q4 2026 earnings at ($0.15) EPS, Q1 2027 earnings at ($0.96) EPS, Q2 2027 earnings at ($1.17) EPS, Q3 2027 earnings at ($0.97) EPS, Q4 2027 earnings at ($0.55) EPS and FY2027 earnings at $0.12 EPS.
Voyager Therapeutics (NASDAQ:VYGR – Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.02. Voyager Therapeutics had a negative return on equity of 63.42% and a negative net margin of 416.32%. The company had revenue of $0.61 million for the quarter, compared to analyst estimates of $6.35 million.
Get Our Latest Stock Report on VYGR
Voyager Therapeutics Stock Up 9.9%
NASDAQ:VYGR opened at $1.67 on Tuesday. Voyager Therapeutics has a 52-week low of $1.48 and a 52-week high of $5.48. The stock has a fifty day simple moving average of $2.27 and a 200-day simple moving average of $3.32.
Institutional Investors Weigh In On Voyager Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of Voyager Therapeutics during the second quarter valued at $18,102,000. Renaissance Technologies LLC raised its stake in Voyager Therapeutics by 95.0% in the 1st quarter. Renaissance Technologies LLC now owns 578,024 shares of the company’s stock valued at $2,231,000 after purchasing an additional 281,574 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in Voyager Therapeutics in the 2nd quarter valued at about $122,000. Hsbc Holdings PLC acquired a new position in Voyager Therapeutics in the 2nd quarter valued at about $117,000. Finally, DLD Asset Management LP purchased a new position in Voyager Therapeutics in the 2nd quarter valued at about $70,000. Hedge funds and other institutional investors own 48.03% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics is a biotechnology company developing genetic medicines for neurological diseases. Its work includes adeno-associated virus (AAV) gene therapies designed to deliver therapeutic genes to the nervous system. The company’s TRACER platform is used to discover and engineer AAV capsids, including candidates intended to cross the blood-brain barrier. Voyager has researched treatments for neurodegenerative and other neurological disorders and has partnered with pharmaceutical companies to advance gene therapy programs.
Featured Articles
- Five stocks we like better than Voyager Therapeutics
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
